Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Non Operating Income (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Non Operating Income for 8 consecutive years, with -$1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 122.78% to -$1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.9 million, a 78.69% decrease, with the full-year FY2024 number at $33.3 million, up 2656.74% from a year prior.
  • Non Operating Income was -$1.1 million for Q3 2025 at Precision Biosciences, up from -$1.6 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $12.8 million in Q1 2024 to a low of -$7.3 million in Q4 2022.
  • A 5-year average of $1.7 million and a median of $96000.0 in 2023 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: surged 31137.04% in 2021, then plummeted 6270.83% in 2022.
  • Precision Biosciences' Non Operating Income stood at $8.4 million in 2021, then tumbled by 186.77% to -$7.3 million in 2022, then skyrocketed by 119.9% to $1.5 million in 2023, then skyrocketed by 387.71% to $7.1 million in 2024, then crashed by 115.56% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Non Operating Income are -$1.1 million (Q3 2025), -$1.6 million (Q2 2025), and $1.5 million (Q1 2025).